PneumRx, Inc., a prominent interventional pulmonology company, recently signed a contract to be acquired by BTG in a deal worth up to $475 million. BTG is an international healthcare company based in London that develops specialty pharmaceuticals. BTG’s existing portfolio in interventional medicine comprises treatments for severe blood clots including pulmonary embolisms, varicose veins, and tumors of the liver. These site-specific therapies are minimally invasive and marketed to specialist physician groups.
Syneron and Candela, a global aesthetic medical device company, has announced that the U.S. Food and Drug Administration (FDA) has approved the PicoWay® picosecond laser for the treatment of pigmented lesions. The PicoWay picosecond laser has also been granted approval by the FDA for the removal of tattoos. PicoWay integrates picosecond (one trillionth of a second) pulse duration to create an ultra-short pulse of high-energy laser on the skin. At high ultra-short picosecond laser pulse at full power produces a photo-mechanical effect that improves fracturing of tattoo ink or pigmentation.
The Food and Drug Administration has approved a cardiac ultrasound system, created by CardioNexus Corp., for the early detection of heart disease.
The potable system uses an ultrasound system for non-invasive heart examinations ouside of an office or clinic setting, and enables physicians to detect arterial plaque and to measure arterial wall thickness.
For more information see this article: <a href=”http://www.bizjournals.com/houston/morning_call/2011/03/cardionexus-nabs-fda-approval-for.html#ixzz1HKn0KyOz”>CardioNexus nabs FDA approval for heart device | Houston Business Journal</a>
Our portfolio company, Neuronetics, Inc., has hired Christopher Thatcher as President & CEO. Welcome Christopher!
Achillion, an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease, announced in a news release that Milind Deshpande, President and CEO of Achillion, and members of the senior management team, will present a corporate update and participate on a HCV Panel at the Wells Fargo 2013 Healthcare Conference on June 18 in Boston, MA. Achillion archives live audio broadcasts and webcasts of Company presentations on the Company’s website, http://www.achillion.com, under the “News Center” section.
CardioFocus was involved in a recent study of a visually guided laser ablation (VGLA) catheter. New catheter designs are in development to address the technical difficulty with achieving pulmonary vein (PV) isolation in the treatment of patients with paroxysmal atrial fibrillation (PAF). The visually-guided laser ablation (VGLA) catheter enables an operator to visualize target tissue for ablation, and then use the laser for point-to-point circumferential ablation. Single center studies demonstrated favorable safety and efficacy. Another study, including the first 200 PAF patients treated with the VGLA, sought to determine the multicenter feasibility, efficacy, and safety of performing PV isolation using the VGLA catheter. In this multicenter experience, PV isolation can be achieved in virtually all patients using a single VGLA catheter with an efficacy similar to radiofrequency ablation. For a full description of this issue, please visit http://bit.ly/11rArF9.
PneumRx, Inc. recently announced that the first U.S. patients have been treated for emphysema with PneumRx’s Lung Volume Reduction Coils (LVRCs), minimally invasive medical implants designed to treat the symptoms of severe emphysema, and to improve lung function, exercise ability and quality of life.
PneumRx’s RePneu LVRC has been used in Europe since 2008. The technology is available to treat patients in Germany, and was selected by the French Ministry of Health in 2012 for a cost-effectiveness study in France. According to PneumRx, the LVRC is intended to treat a broad range of emphysema patients, including those with heterogeneous and homogeneous disease, in both upper and lower lobes, and it performs independently of collateral ventilation, a common condition in emphysema patients.
The patients in the FDA-approved U.S. study were treated by Dr. Charlie Strange, Medical University of South Carolina, and Dr. Frank Sciurba, University of Pittsburgh and UPMC. Up to 315 patients in more than 25 medical centers across North America, plus centers in the Netherlands, UK and Germany, will participate in the study.
PneumRx develops minimally invasive medical devices, seeking to meet the market need for better treatments for emphysema patients.
Achillion Pharmaceuticals, Inc., a pharmaceutical company dedicated to bringing new treatments to patients with infectious disease, announced that it will present a corporate update at the Leerink Swann Global Healthcare Conference on Wednesday, February 13, 2013 at the Waldorf-Astoria Hotel in New York. Michael Kishbauch, President and Chief Executive Officer of Achillion, will make the presentation. Achillion is focused on solutions for the most challenging problems in infectious disease including the hepatitis C virus (HCV) and resistant bacterial infections. According to an Achillion news release, a live audio and video broadcast will be available on the Company’s website,http://www.achillion.com, under the “News Center” section, to be archived on the site for 30 days. Those who wish to view the live broadcast should connect to Achillion’s website several minutes prior to the start of the presentation.
CardioFocus, Inc., a medical device manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), is the developer of the HeartLight® Endoscopic Ablation System for the treatment of AF. The HeartLight technology possesses unique capabilities for the treatment of AF, enabling physicians to directly see the tissue to be ablated, and offering a laser energy source to facilitate the creation of durable lesions.
As of late 2012, more than 1,000 clinical cases have been performed worldwide using the HeartLight technology. CardioFocus recently held an expert symposium in Boston, MA, to review the clinical application of HeartLight and observations from the first 1,000 cases.
Presentations covered techniques for utilizing the endoscopically-guided ablation system, the desired location of pulmonary vein isolation, and the impact of HeartLight laser energy titration on achieving durable results. Discussion covered clinical results obtained using HeartLight in comparison to systems using alternative energy sources.
Temple University Hospital is testing the RePneu® Lung Volume Reduction Coils as part of a study on lung volume reduction coil treatment in patients with emphysema, which is being conducted by California‐based PneumRx, the company that makes the coils. The testing seeks to determine whether implanting miniature coils in the airways of diseased lungs of emphysema patients can improve breathing, activity levels and quality of life.
The coils – which are made with Nitinol, a metal commonly used in medical implants – compress damaged tissue, enabling healthier portions of the lung to function more efficiently, easing breathing in the process. The coils stand as a minimally invasive alternative to lung volume reduction surgery. European studies have shown that patients treated with the coils experience improved quality of life, greater ability to exercise and reduced breathlessness.
RePneu coils are delivered through a bronchoscope in a short, non‐surgical procedure performed under conscious sedation or general anesthesia. A typical procedure takes approximately 30 minutes and involves the implantation of approximately 10 coils.